A single retrospective study found a slight increase in melanoma risk in patients treated with anti-TNF-α therapy for IBD, although no such relationship was found in larger series that have pooled patients receiving anti-TNF-α therapy for a variety of indications (60, 61). This evidence concerns the gene TNF and inflammatory bowel disease.